Trial Profile
A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 29 Mar 2018 New trial record
- 29 Mar 2018 New trial record